The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis

1. Genovese, MC, Smolen, JS, Weinblatt, ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol 2016; 68: 2857–2866.
Google Scholar | Crossref | Medline2. Kremer, JM, Emery, P, Camp, HS, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol 2016; 68: 2867–2877.
Google Scholar | Crossref | Medline3. Mohamed, MF, Camp, HS, Jiang, P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet 2016; 55: 1547–1558.
Google Scholar | Crossref | Medline4. Avci, AB, Feist, E, Burmester, GR. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology 2021; 60(Suppl. 2): ii11–ii16.
Google Scholar | Crossref | Medline5. Burmester, GR, Kremer, JM, Van den Bosch, F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391: 2503–2512.
Google Scholar | Crossref | Medline6. Genovese, MC, Fleischmann, R, Combe, B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018; 391: 2513–2524.
Google Scholar | Crossref | Medline7. Smolen, JS, Pangan, AL, Emery, P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019; 393: 2303–2311.
Google Scholar | Crossref | Medline8. van Vollenhoven, R, Takeuchi, T, Pangan, AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol 2020; 72: 1607–1620.
Google Scholar | Crossref | Medline9. Fleischmann, R, Pangan, AL, Song, IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019; 71: 1788–1800.
Google Scholar | Crossref | Medline10. Kameda, H, Takeuchi, T, Yamaoka, K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology 2020; 59: 3303–3313.
Google Scholar | Crossref | Medline11. Rubbert-Roth, A, Enejosa, J, Pangan, AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 2020; 383: 1511–1521.
Google Scholar | Crossref | Medline12. [email protected]: FDA-approved drugs , https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211675 (accessed 16 May 2021).
Google Scholar13. EMA , https://www.ema.europa.eu/en/documents/overview/rinvoq-epar-medicine-overview_en.pdf (accessed 16 May 2021).
Google Scholar14. Strand, V, Pope, J, Tundia, N, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther 2019; 21: 272.
Google Scholar | Crossref | Medline15. Strand, V, Schiff, M, Tundia, N, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther 2019; 21: 263.
Google Scholar | Crossref | Medline16. Fleischmann, RM, Genovese, MC, Enejosa, JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 2019; 78: 1454–1462.
Google Scholar | Crossref | Medline17. Conaghan, PG, Mysler, E, Tanaka, Y, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf 2021; 44: 515–530.
Google Scholar | Crossref | Medline18. Cohen, S, Van Vollenhoven, R, Curtis, J, et al. Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis [Abstract]. Arthritis Rheumatol 2020; 72(Suppl. 10), https://acrabstracts.org/abstract/safety-profile-of-upadacitinib-up-to-3-years-of-exposure-in-patients-with-rheumatoid-arthritis/ (ACR Convergence 2020).
Google Scholar19. Winthrop, K, Calabrese, L, Van den Bosch, F, et al. Characterization of serious infections with upadacitinib in patients with rheumatoid arthritis [Abstract]. Arthritis Rheumatol 2020; 72(Suppl. 10), https://acrabstracts.org/abstract/Characterization-of-serious-infections-with-upadacitinib-in-patients-with-rheumatoid-arthritis/ (ACR Convergence 2020).
Google Scholar20. Winthrop, K, Nash, P, Yamaoka, K, et al. Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib [Abstract]. Arthritis Rheumatol 2020; 72(Suppl. 10), https://acrabstracts.org/abstract/incidence-and-risk-factors-for-herpes-zoster-in-rheumatoid-arthritis-patients-receiving-upadacitinib/ (ACR Convergence 2020).
Google Scholar21. Solipuram, V, Mohan, A, Patel, R, et al. Effect of Janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Auto Immun Highlights 2021; 12: 8.
Google Scholar | Crossref | Medline22. FDA . Tofacitinib medical review (Application number 203214Orig1s000), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000MedR.pdf (2012, accessed 16 May 2021).
Google Scholar23. FDA . Tocilizumab medical review (Application number 125276), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000MedR.pdf (2009, accessed 16 May 2021).
Google Scholar24. FDA , https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000SumR.pdf (accessed 16 May 2021).
Google Scholar25. Cohen, SB, van Vollenhoven, RF, Winthrop, KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 2020; 80: 304–311.
Google Scholar | Crossref26. Kameda, H, Takeuchi, T, Yamaoka, K, et al. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther 2021; 23: 9.
Google Scholar | Crossref | Medline27. Weng, C, Xue, L, Wang, Q, et al. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. Ther Adv Musculoskelet Dis 2021; 13: 1759720X21999564.
Google Scholar | SAGE Journals28. Pope, J, Sawant, R, Tundia, N, et al. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther 2020; 37: 2356–2372.
Google Scholar | Crossref | Medline29. Lee, YH, Song, GG. Relative Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib im Vergleich zu Adalimumab bei Patienten mit aktiver rheumatoider Arthritis [Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis]. Z Rheumatol 2020; 79: 785–796.
Google Scholar | Crossref | Medline30. Song, GG, Choi, SJ, Lee, YH. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis 2019; 22: 1563–1571.
Google Scholar | Crossref | Medline31. Tanaka, Y . A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol 2020; 30: 779–787.
Google Scholar | Crossref | Medline32. Winthrop, KL . The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017; 13: 320.
Google Scholar | Crossref | Medline33. Cohen, SB, Tanaka, Y, Mariette, X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open 2020; 6: e001395.
Google Scholar | Crossref | Medline34. Smolen, JS, Genovese, MC, Takeuchi, T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 2019; 46: 7–18.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif